# Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19

> **NCT04473170** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abu Dhabi Stem Cells Center** · enrollment: 146 (actual)

## Conditions studied

- Coronavirus Disease 2019 (COVID-19)

## Interventions

- **BIOLOGICAL:** Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)
- **DRUG:** COVID-19 standard care

## Key facts

- **NCT ID:** NCT04473170
- **Lead sponsor:** Abu Dhabi Stem Cells Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-04
- **Primary completion:** 2020-05-20
- **Final completion:** 2020-07-14
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2020-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04473170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04473170, "Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04473170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*